Clinical Trial Update: Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor [Phase 4]

View source ↗

Summary

Phase 4 trial investigating dopaminergic modulation of frontostriatal function with a dopamine agonist and COMT inhibitor for addiction was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Addiction

Snippet

Sponsor: University of California, Berkeley | Conditions: Addiction | Phase 4 | Status: WITHDRAWN